BETA BIONICS INC (BBNX) — insider trading
Health Care · NASDAQ
BETA BIONICS INC (BBNX) has 22 reported SEC Form 4 insider transactions in our data, including 13 open-market sales among the most recent 22 (latest 2026-06-29).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | Feider Stephen | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 4,896 | $0.00 | $0 | Form 4/A |
| 2026-06-29 | Feider Stephen | Officer (Chief Financial Officer) | Open-market sale | 4,896 | $17.03 | $83.4K | Form 4/A |
| 2026-06-29 | Feider Stephen | Officer (Chief Financial Officer) | Option exercise / conversion | 4,896 | $5.10 | $25.0K | Form 4/A |
| 2026-06-29 | Feider Stephen | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 4,896 | $0.00 | $0 | Form 4 |
| 2026-06-29 | Feider Stephen | Officer (Chief Financial Officer) | Open-market sale | 4,896 | $17.03 | $83.4K | Form 4 |
| 2026-06-29 | Feider Stephen | Officer (Chief Financial Officer) | Option exercise / conversion | 4,896 | $5.10 | $25.0K | Form 4 |
| 2026-06-26 | Feider Stephen | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 5,104 | $0.00 | $0 | Form 4/A |
| 2026-06-26 | Feider Stephen | Officer (Chief Financial Officer) | Open-market sale | 5,104 | $17.05 | $87.0K | Form 4/A |
| 2026-06-26 | Feider Stephen | Officer (Chief Financial Officer) | Option exercise / conversion | 5,104 | $5.10 | $26.0K | Form 4/A |
| 2026-06-26 | Feider Stephen | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 4,982 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Feider Stephen | Officer (Chief Financial Officer) | Open-market sale | 5,104 | $17.05 | $87.0K | Form 4 |
| 2026-06-26 | Feider Stephen | Officer (Chief Financial Officer) | Option exercise / conversion | 4,982 | $5.10 | $25.4K | Form 4 |
| 2026-06-24 | Jones Christy | Director | Open-market sale | 1,406 | $15.00 | $21.1K | Form 4 |
| 2026-06-24 | Hopman Mark | Officer (Chief Commercial Officer) | Open-market sale | 1,258 | $15.01 | $18.9K | Form 4 |
| 2026-06-04 | Jones Christy | Director | Open-market sale | 2,811 | $14.00 | $39.4K | Form 4 |
| 2026-06-04 | Hopman Mark | Officer (Chief Commercial Officer) | Open-market sale | 275 | $12.31 | $3.4K | Form 4 |
| 2026-06-02 | Saint Sean | Director, Officer (President & CEO) | Open-market sale | 16,872 | $12.61 | $212.7K | Form 4 |
| 2026-06-02 | Feider Stephen | Officer (Chief Financial Officer) | Open-market sale | 6,676 | $12.61 | $84.2K | Form 4 |
| 2026-06-02 | Russell Steven Jon | Officer (Chief Medical Officer) | Open-market sale | 4,222 | $12.61 | $53.2K | Form 4 |
| 2026-06-02 | Hopman Mark | Officer (Chief Commercial Officer) | Open-market sale | 5,329 | $12.61 | $67.2K | Form 4 |
| 2026-06-02 | Mensinger Mike | Officer (Chief Product Officer) | Open-market sale | 4,378 | $12.61 | $55.2K | Form 4 |
| 2026-05-21 | MICHEL GERARD J | Director | Grant / award / vesting | 16,965 | $0.00 | $0 | Form 4 |
Ask the chat about BBNX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: BETA BIONICS INC (BBNX).
Last updated 2026-06-29 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.